MEG3 and non-small cell lung carcinoma: Lv et al. found that MEG3 inhibits migration and invasion of NSCLC cells and enhances PTEN expression via the PI3K/AKT signaling pathway, suggesting its potential as a novel therapeutic target for NSCLC64.